image: Diwakar Davar, M.D., associate professor of medicine at the University of Pittsburgh and co-leader of the Cancer Immunology and Immunotherapy Program at UPMC Hillman Cancer Center
Credit: UPMC
PITTSBURGH, Nov. 17, 2026 – Protein patterns in melanoma tumors can predict how patients respond to immunotherapy and can be used to find promising biomarkers and drug targets, according to two new University of Pittsburgh studies.
The companion studies, published today in Cancer Discovery and Clinical Cancer Research, journals of the American Association for Cancer Research, developed a molecular atlas of melanoma and method of classifying and predicting immunotherapy response based on protein patterns. Determining which patients are most likely to respond to immunotherapy before treatment begins may allow patients who are unlikely to benefit to avoid harmful side effects and prevent delays in starting better treatment options.
Immune checkpoint inhibitors, a type of cancer immunotherapy, have dramatically improved melanoma patient survival in the last 15 years. But a large percentage of patients don't respond to the treatment, and biomarkers that predict treatment response remain elusive. To better understand why some patients are resistant to the treatment, researchers looked to the proteome, the entire set of proteins expressed in a tissue or organism.
“In 2003, we decoded the human genome. However, because proteins are the actual molecular machines that carry out the work of life, characterizing the proteomic states of tumors is critical to both understanding both the biology of tumors and identifying prognostic biomarkers,” says co-senior author Diwakar Davar, M.D., associate professor of medicine at Pitt and co-leader of the Cancer Immunology and Immunotherapy Program at UPMC Hillman Cancer Center. “Protein atlases bridge the gap between genomic possibility and therapeutic reality.”
The Cancer Discovery study characterized pre-treatment melanomas from 183 patients, simultaneously analyzing 13 molecular levels, including the genome, proteome and metabolome (all the metabolites in a tissue or organism). This approach, called multi-omics, yielded a comprehensive atlas that not only provides a clearer picture of the melanoma tumor microenvironment, but also serves as a foundation for discovering new biomarkers and drugs. The research team identified chemical alterations to proteins that are associated with survival as well as hundreds of potential targets for future investigations.
“To understand the proteomic landscape in melanoma, we needed two different sets of analyses,” says Davar. “The primary tumor analysis linked changes in the genome to their protein consequences, revealing therapeutic vulnerabilities and protein patterns in untreated melanoma tumors. The characterization of melanoma tumors before combination immunotherapy revealed the tumor and immune properties that shape sensitivity or resistance to the treatment.”
The Clinical Cancer Research study used data from 208 tumors samples obtained from patients with melanoma prior to immunotherapy, through an international collaboration with contributions from all NCI-funded Melanoma SPORE programs. The research team identified three subtypes characterized by distinct protein patterns. One group had increased immune activity, one had elevated features of cell proliferation, and one had characteristics associated with tumor growth and metastasis.
Each of these protein pattern groups was differentially associated with treatment response, with the immune-rich group being the most responsive. Among patients who received combination immunotherapy, subtypes were also associated with disease progression and survival, suggesting protein patterns can be used to predict how patients will respond to treatment.
Researchers then trained a classifier model to use protein patterns to sort tumors into one of the three groups. This classifier, independently validated in two patient cohorts, was able to predict treatment response type and progression-free survival with a high degree of certainty.
Further validation of the findings is needed, but the research lays the groundwork for developing more personalized immunotherapy that considers a patient's likely responsiveness and prognosis before treatment begins.
“We currently lack robust biomarkers to predict which patients will derive benefit from combination immunotherapy. A proteomic biomarker could identify tumors most likely to respond, providing the foundation for a clinical assay to guide treatment selection,” said Davar. “Once translated into a validated clinical assay, the biomarker could allow pathology laboratories across the country, from Pittsburgh to Palm Beach, to help determine whether a patient is likely to benefit from treatment.”
Pei Wang, Ph.D., of Icahn School of Medicine, Amanda Paulovich, M.D., Ph.D., of at Fred Hutchinson Cancer Center, Marcin Cieslik, Ph.D., of University of Michigan, and Tao Liu, Ph.D., of Pacific Northwest National Laboratory are the co-senior and co-corresponding authors of current studies.
This research received support from the National Cancer Institute Clinical Proteomic Tumor Analysis Consortium (U24CA270823, U24CA271079, U24CA271012, U24CA271075, U24CA271076, U24CA271037, U24CA271114, U01CA271412, U01CA271410, U01CA271407, U01CA271402), National Institutes of Health (75N91019D00024, 75N91020F00030), National Cancer Institute (P30 CA015704, R50 CA211499, P50 CA225450, U54 CA263001, P50 CA121974), National Center for Advancing Translational Sciences (UL1TR004419), NIH Office of Research Infrastructure Programs (S10OD026880, S10OD030463, S10OD030225, S10OD028685), National Health and Medical Research Council of Australia (2022/GNT2018514), NIH Specialized Program of Research Excellence (SPORE) Melanoma Grant (P50 CA93459), and the Aven Foundation.
Journal
Clinical Cancer Research
Article Title
Identification of Proteomic Subtypes with Differential Responses to Immune Checkpoint Inhibition in Cutaneous Melanoma
Article Publication Date
17-Nov-2026